Preclinical Evaluation of 177Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy.

177Lu-rhPSMA-10.1 - Bracco

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis

http://www.ncbi.nlm.nih.gov/pubmed/40049746

Bart Cornelissen; Bradley Waldron; Caroline Foxton; Daniel Stevens; Edward O'Neill; Jaime Jim Simón; Rikke Veggerby Grønlund

Mar 7, 2025